Page last updated: 2024-11-13

quad pill

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination: A pharmaceutical preparation of the ANTI-HIV AGENTS elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate that is used in the treatment of HIV INFECTIONS. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID44232548
MeSH IDM000606071

Synonyms (12)

Synonym
stribild
FMCLRHTZMTUYMI-JFQFMQNHSA-N
cobicistat / elvitegravir / emtricitabine / tenofovir disoproxil fumarate
quad tablet
cobicistat, elvitegravir, emtricitabine, tenofovir
quad
quad pill
cobicistat / elvitegravir / emtricitabine / tenofovir disoproxil
elvitegravir-cobicistat-emtricitabine-tenofovir disoproxil fumarate
elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate drug combination
1430117-57-9
evg-cobi-ftc-tdf

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" We evaluated incidence and treatment-related adverse events, including change in serum creatinine (SCr)."( Safety and Tolerability of Stribild in the Southeast United States.
Bookstaver, PB; Caulder, CR; Derrick, CB; Hester, EK; Lu, ZK; Wagner, TD, 2016
)
0.43
"Our results demonstrate limited adverse events and low discontinuation rates associated with EVG/COBI/TDF/FTC."( Safety and Tolerability of Stribild in the Southeast United States.
Bookstaver, PB; Caulder, CR; Derrick, CB; Hester, EK; Lu, ZK; Wagner, TD, 2016
)
0.43
" Phase II and III randomized clinical trials evaluate the efficacy and safety of EVG/c/TAF/FTC and tenofovir disoproxil fumerate (TDF)-containing arms; renal impairment, bone mineral density, metabolic effects, and other adverse events are topics explored within this review."( A Review of the Efficacy and Safety of Genvoya® (Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide) in the Management of HIV-1 Infection.
Angione, SA; Cherian, SM; Özdener, AE, 2018
)
0.48
" The most common adverse events were diarrhea, nausea, and headache."( A Review of the Efficacy and Safety of Genvoya® (Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide) in the Management of HIV-1 Infection.
Angione, SA; Cherian, SM; Özdener, AE, 2018
)
0.48
" Data seem to suggest it may also be effective and safe in patients with mild to moderate renal impairment."( A Review of the Efficacy and Safety of Genvoya® (Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide) in the Management of HIV-1 Infection.
Angione, SA; Cherian, SM; Özdener, AE, 2018
)
0.48

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic assessments occurred on days 7, 28, 35, and 42; trough samples (Ctrough) were collected periodically until day 63."( Pharmacokinetics of Co-Formulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate After Switch From Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Healthy Subjects.
Custodio, JM; Dave, A; Fordyce, M; Kearney, BP; Ling, KH; Ramanathan, S; Szwarcberg, J; Wang, H; Wei, X, 2016
)
0.43
" CYP2B6 poor metabolizers displayed higher EFV AUCtau and Cmax (125% and 91%, respectively) versus non-poor metabolizers, and lower EVG and COBI exposures."( Pharmacokinetics of Co-Formulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate After Switch From Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Healthy Subjects.
Custodio, JM; Dave, A; Fordyce, M; Kearney, BP; Ling, KH; Ramanathan, S; Szwarcberg, J; Wang, H; Wei, X, 2016
)
0.43
" The pharmacokinetic parameters (Cmax , AUCtau , and Ctau ) of elvitegravir were investigated at Day 10 after each treatment, together with safety and tolerability."( Pharmacokinetic and bioequivalence evaluation of single-tablet and separate-tablet regimens for once-daily cobicistat-boosted elvitegravir in healthy Japanese male subjects: A randomized, two-way crossover study.
Ikeda, A; Irie, S; Ishikawa, T; Kimura, M; Kumagai, Y; Matsuki, S; Nishino, N; Shiomi, M,
)
0.13

Bioavailability

ExcerptReferenceRelevance
"This randomized, two-way crossover study evaluated the bioavailability of elvitegravir administered as the new individual tablet containing 150 mg and a cobicistat 150 mg tablet, concomitantly with a fixed-dose combination tablet containing 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate (EVG + COBI + FTC/TDF), in comparison with a single-tablet regimen containing the same dose of each component (EVG/COBI/FTC/TDF)."( Pharmacokinetic and bioequivalence evaluation of single-tablet and separate-tablet regimens for once-daily cobicistat-boosted elvitegravir in healthy Japanese male subjects: A randomized, two-way crossover study.
Ikeda, A; Irie, S; Ishikawa, T; Kimura, M; Kumagai, Y; Matsuki, S; Nishino, N; Shiomi, M,
)
0.13

Dosage Studied

ExcerptRelevanceReference
"Fixed-dose combination of elvitegravir/cobicistat/TDF/FTC was safe and well tolerated for PEP, with higher regimen completion rates than more frequently dosed PEP regimens."( Optimal HIV Postexposure Prophylaxis Regimen Completion With Single Tablet Daily Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine Compared With More Frequent Dosing Regimens.
Gelman, M; Grasso, C; Jain, S; Jones, D; Mayer, KH; Mimiaga, MJ; Oldenburg, C; Zaslow, S, 2017
)
0.46
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (40)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's34 (85.00)24.3611
2020's6 (15.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 30.34

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index30.34 (24.57)
Research Supply Index3.91 (2.92)
Research Growth Index4.57 (4.65)
Search Engine Demand Index28.17 (26.88)
Search Engine Supply Index1.56 (0.95)

This Compound (30.34)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials6 (13.95%)5.53%
Reviews7 (16.28%)6.00%
Case Studies9 (20.93%)4.05%
Observational2 (4.65%)0.25%
Other19 (44.19%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]